Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03639623 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)
A Phase 2 study, sponsored by Zydus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03639623 is a Phase 2 study that has completed, run by Zydus Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT03639623, a Phase 2 study, has completed, sponsored by Zydus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.
Interventions
- DRUG Saroglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-02-25 |
| Est. Completion | 2021-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03639623
The ClinicalTrials.gov registry entry for NCT03639623 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zydus Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saroglitazar is the first listed.
NCT03639623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03639623 about?
NCT03639623 is a clinical study titled "Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)". This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.
What is the current status of trial NCT03639623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-02-25. Estimated completion is 2021-12-13.
What interventions are being tested in trial NCT03639623?
The interventions under investigation include: Saroglitazar (DRUG).
Who is sponsoring clinical trial NCT03639623?
This trial is sponsored by Zydus Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.